Cross-Sectional Associations Among Symptoms of Pain, Irritability, and Depression and How These Symptoms Relate to Social Functioning and Quality of Life: Findings From the EMBARC and STRIDE Studies and the VitalSign6 Project

References (66)

1. Vos T, Abajobir AA, Abbafati C, et al; GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–1259. PubMed CrossRef
2. Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163(20):2433–2445. PubMed CrossRef
3. Ohayon MM, Schatzberg AF. Chronic pain and major depressive disorder in the general population. J Psychiatr Res. 2010;44(7):454–461. PubMed CrossRef
4. Arnow BA, Hunkeler EM, Blasey CM, et al. Comorbid depression, chronic pain, and disability in primary care. Psychosom Med. 2006;68(2):262–268. PubMed CrossRef
5. Vaccarino AL, Sills TL, Evans KR, et al. Multiple pain complaints in patients with major depressive disorder. Psychosom Med. 2009;71(2):159–162. PubMed CrossRef
6. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry. 2003;60(1):39–47. PubMed CrossRef
7. Owen-Smith A, Stewart C, Sesay MM, et al. Chronic pain diagnoses and opioid dispensings among insured individuals with serious mental illness. BMC Psychiatry. 2020;20(1):40. PubMed CrossRef
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American Psychiatric Association; 2013.
9. Fava M, Hwang I, Rush AJ, et al. The importance of irritability as a symptom of major depressive disorder: results from the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15(8):856–867. PubMed CrossRef
10. Jha MK, Minhajuddin A, Chin Fatt C, et al. Association between irritability and suicidal ideation in three clinical trials of adults with major depressive disorder. Neuropsychopharmacology. 2020;45(13):2147–2154. PubMed CrossRef
11. Jha MK, Minhajuddin A, South C, et al. Irritability and its clinical utility in major depressive disorder: prediction of individual-level acute-phase outcomes using early changes in irritability and depression severity. Am J Psychiatry. 2019;176(5):358–366. PubMed CrossRef
12. Judd LL, Schettler PJ, Coryell W, et al. Overt irritability/anger in unipolar major depressive episodes: past and current characteristics and implications for long-term course. JAMA Psychiatry. 2013;70(11):1171–1180. PubMed CrossRef
13. Orri M, Perret LC, Turecki G, et al. Association between irritability and suicide-related outcomes across the life-course. systematic review of both community and clinical studies. J Affect Disord. 2018;239:220–233. PubMed CrossRef
14. Toohey MJ, DiGiuseppe R. Defining and measuring irritability: construct clarification and differentiation. Clin Psychol Rev. 2017;53:93–108. PubMed CrossRef
15. Holtzman S, O’Connor BP, Barata PC, et al. The Brief Irritability Test (BITe): a measure of irritability for use among men and women. Assessment. 2015;22(1):101–115. PubMed CrossRef
16. Jha MK, Minhajuddin A, Greer TL, et al. Early improvement in work productivity predicts future clinical course in depressed outpatients: findings from the CO-MED Trial. Am J Psychiatry. 2016;173(12):1196–1204. PubMed CrossRef
17. Trivedi MH, Morris DW, Wisniewski SR, et al. Increase in work productivity of depressed individuals with improvement in depressive symptom severity. Am J Psychiatry. 2013;170(6):633–641. PubMed CrossRef
18. Jha MK, Minhajuddin A, Greer TL, et al. Early improvement in psychosocial function predicts longer-term symptomatic remission in Depressed Patients. PLoS One. 2016;11(12):e0167901. PubMed CrossRef
19. Hays RD, Wells KB, Sherbourne CD, et al. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry. 1995;52(1):11–19. PubMed CrossRef
20. Jha MK, Greer TL, Grannemann BD, et al. Early normalization of quality of life predicts later remission in depression: findings from the CO-MED trial. J Affect Disord. 2016;206:17–22. PubMed CrossRef
21. Ishak WW, Christensen S, Sayer G, et al. Sexual satisfaction and quality of life in major depressive disorder before and after treatment with citalopram in the STAR*D study. J Clin Psychiatry. 2013;74(3):256–261. PubMed CrossRef
22. Jha MK, Teer RB, Minhajuddin A, et al. Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder. Neuropsychiatr Dis Treat. 2017;13:803–813. PubMed CrossRef
23. Jha MK, South C, Trivedi J, et al. Prediction of acute-phase treatment outcomes by adding a single-item measure of activity impairment to symptom measurement: development and validation of an interactive calculator from the STAR*D and CO-MED Trials. Int J Neuropsychopharmacol. 2019;22(5):339–348. PubMed CrossRef
24. Trivedi MH, McGrath PJ, Fava M, et al. Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. J Psychiatr Res. 2016;78:11–23. PubMed CrossRef
25. Trivedi MH, South C, Jha MK, et al. A novel strategy to identify placebo responders: prediction index of clinical and biological markers in the EMBARC Trial. Psychother Psychosom. 2018;87(5):285–295. PubMed CrossRef
26. Trivedi MH, Greer TL, Grannemann BD, et al. Stimulant reduction intervention using dosed exercise (STRIDE) - CTN 0037: study protocol for a randomized controlled trial. Trials. 2011;12(1):206. PubMed CrossRef
27. Trivedi MH, Jha MK, Kahalnik F, et al. VitalSign⁶: a Primary Care First (PCP-First) model for universal screening and measurement-based care for depression. Pharmaceuticals (Basel). 2019;12(2):71. PubMed CrossRef
28. dela Cruz AM, Bernstein IH, Greer TL, et al. Self-rated measure of pain frequency, intensity, and burden: psychometric properties of a new instrument for the assessment of pain. J Psychiatr Res. 2014;59:155–160. PubMed CrossRef
29. Krebs EE, Carey TS, Weinberger M. Accuracy of the pain numeric rating scale as a screening test in primary care. J Gen Intern Med. 2007;22(10):1453–1458. PubMed CrossRef
30. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. New York, NY; SCID-I/P; 2002.
31. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–583. PubMed CrossRef
32. Chandler GM, Iosifescu DV, Pollack MH, et al. RESEARCH: validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 2010;16(5):322–325. PubMed CrossRef
33. Trivedi MH, Greer TL, Rethorst CD, et al. Randomized controlled trial comparing exercise to health education for stimulant use disorder: results from the CTN-0037 STimulant Reduction Intervention Using Dosed Exercise (STRIDE) Study. J Clin Psychiatry. 2017;78(8):1075–1082. PubMed CrossRef
34. Chartier KG, Sanchez K, Killeen TK, et al. Men and women from the STRIDE clinical trial: an assessment of stimulant abstinence symptom severity at residential treatment entry. Am J Addict. 2015;24(4):336–340. PubMed CrossRef
35. Jha MK, Grannemann BD, Trombello JM, et al. A structured approach to detecting and treating depression in primary care: VitalSign6 Project. Ann Fam Med. 2019;17(4):326–335. PubMed CrossRef
36. Löwe B, Kroenke K, Gräfe K. Detecting and monitoring depression with a two-item questionnaire (PHQ-2). J Psychosom Res. 2005;58(2):163–171. PubMed CrossRef
37. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613. PubMed CrossRef
38. Jha MK, Minhajuddin A, South C, et al. Worsening anxiety, irritability, insomnia, or panic predicts poorer antidepressant treatment outcomes: clinical utility and validation of the Concise Associated Symptom Tracking (CAST) Scale. Int J Neuropsychopharmacol. 2018;21(4):325–332. PubMed CrossRef
39. Minhajuddin A, Jha MK, Chin Fatt C, et al. Psychometric properties of the concise associated symptom tracking scale and validation of clinical utility in the EMBARC study. Psychiatric Res Clin Prac. 2020;2(1):10–18. CrossRef
40. Gameroff MJ, Wickramaratne P, Weissman MM. Testing the short and screener versions of the Social Adjustment Scale-Self-report (SAS-SR). Int J Methods Psychiatr Res. 2012;21(1):52–65. PubMed CrossRef
41. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321–326. PubMed
42. Pollack MH, Endicott J, Liebowitz M, et al. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res. 2008;42(12):1042–1049. PubMed CrossRef
43. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–365. PubMed CrossRef
44. Hooper D, Coughlan J, Mullen M. Structural equation modelling: guidelines for determining model fit. Electronic Journal of Business Research Methods. 2008;6(1):53–60.
45. Samejima F. Graded reponse model. In: van der Linden WJ, Hambleton RK, eds. Handbook of Modern Item Response Theory. New York, New York: Springer-Verlag; 1997.
46. Rush AJ, South CC, Jha MK, et al. Toward a very brief Quality of Life Enjoyment and Satisfaction Questionnaire. J Affect Disord. 2019;242:87–95. PubMed CrossRef
47. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16(3):297–334. CrossRef
48. Villarroel MA, Terlizzi EP. Symptoms of depression among adults: United States, 2019. NCHS Data Brief, no 379. Hyattsville, MD: National Center for Health Statistics; 2020. https://www.cdc.gov/nchs/products/databriefs/db379.htm Accessed December 28, 2020.
49. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51(6):1173–1182. PubMed CrossRef
50. Eshel N, Leibenluft E. New frontiers in irritability research-from cradle to grave and bench to bedside. JAMA Psychiatry. 2019;77(3):227–228. PubMed
51. van Bronswijk S, Moopen N, Beijers L, et al. Effectiveness of psychotherapy for treatment-resistant depression: a meta-analysis and meta-regression. Psychol Med. 2019;49(3):366–379. PubMed CrossRef
52. Boschloo L, Bekhuis E, Weitz ES, et al. The symptom-specific efficacy of antidepressant medication vs cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis. World Psychiatry. 2019;18(2):183–191. PubMed CrossRef
53. Cherkin DC, Anderson ML, Sherman KJ, et al. Two-year follow-up of a randomized clinical trial of mindfulness-based stress reduction vs cognitive behavioral therapy or usual care for chronic low back pain. JAMA. 2017;317(6):642–644. PubMed CrossRef
54. Fisher E, Law E, Dudeney J, et al. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. 2018;9(9):CD003968. PubMed
55. Kircanski K, Clayton ME, Leibenluft E, et al. Psychosocial treatment of irritability in youth. Curr Treat Options Psychiatry. 2018;5(1):129–140. PubMed CrossRef
56. Kircanski K, Craske MG, Averbeck BB, et al. Exposure therapy for pediatric irritability: theory and potential mechanisms. Behav Res Ther. 2019;118:141–149. PubMed CrossRef
57. Scher C, Meador L, Van Cleave JH, et al. Moving beyond pain as the fifth vital sign and patient satisfaction scores to improve pain care in the 21st c Pain Manag Nurs. 2018;19(2):125–129. PubMed CrossRef
58. LaVance MS, Fairchild R, Rosado RJ. Turning the table: depression screening as the 6th vital sign. J Nurse Pract. 2015;11(2):199–206. CrossRef
59. Walker AK, Kavelaars A, Heijnen CJ, et al. Neuroinflammation and comorbidity of pain and depression. Pharmacol Rev. 2013;66(1):80–101. PubMed CrossRef
60. Sheng J, Liu S, Wang Y, et al. The link between depression and chronic pain: neural mechanisms in the brain. Neural Plast. 2017;2017:9724371. PubMed CrossRef
61. Papakostas GI, Salloum NC, Hock RS, et al. Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis. J Clin Psychiatry. 2020;81(4):19r12889. PubMed CrossRef
62. McIntyre RS, Lipsitz O, Rodrigues NB, et al. The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. Bipolar Disord. 2020;22(8):831–840. PubMed CrossRef
63. Brotman MA, Kircanski K, Leibenluft E. Irritability in children and adolescents. Annu Rev Clin Psychol. 2017;13(1):317–341. PubMed CrossRef
64. Leibenluft E. Irritability in children: what we know and what we need to learn. World Psychiatry. 2017;16(1):100–101. PubMed CrossRef
65. Jha MK, Fava M, Minhajuddin A, et al. Association of anger attacks with suicidal ideation in adults with major depressive disorder: findings from the EMBARC study. Depress Anxiety. 2020;38(1)57–66. PubMed
66. Jha MK, Fava M, Minhajuddin A, et al. Anger attacks are associated with persistently elevated irritability in MDD: findings from the EMBARC study. Psychol Med. 2020;6:1–9. PubMed CrossRef